Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
QCLS Catalyst Timeline
Dated clinical, regulatory and corporate events for Q/C Technologies, Inc.
Past FDA Catalysts and PDUFA Decisions
How QCLS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
No drug pipeline
Q/C Technologies, Inc. is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every QCLS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| MYMD-1 | sarcopenia | Phase 2 | 2023-10-04 | statistical significance in reducing serum levels of TNF- , IL-6 and sTNFR1; reduction in TNF- across 28 days versus placebo (p=0.002 to 0.008)Read More | MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF- Market Disrupter, at BioFuture 2023 - Company to share new positive, statistically significant results across CohoRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Voss Chelsea SierraDirector | Grant/Award | 50,000 50,000 held | $0.00 | 04/13/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in QCLS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in QCLS for Q2 2026. | ||||
Ownership Trends
QCLS Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How QCLS ranks across every disease it competes in
QCLS News
Q/C Technologies Reports Over $10 Million in Cash and Investments to Fund Development of Its Optical Processing Unit
Q/C Technologies reported over $10 million in cash to fund its Optical Processing Unit (OPU) development. The OPU aims to enhance AI computations using light, targeting energy efficiency. Initial designs are expected by the end of 2026, with a hardware demonstration planned for 2027. The company is led by CTO Yossi Ehrlichman, who has significant expertise in optical computing.
Read more →Q/C Technologies Announces Research Collaboration with Sandia National Laboratories, a $5 Billion U.S. Department of Energy Lab
Q/C Technologies has partnered with Sandia National Laboratories to advance its optical processing unit initiative for AI inference. This collaboration focuses on research in nanophotonics and aims to establish a roadmap for scalable optical AI processing. The company recently opened a new integrated photonics lab to support this initiative.
Read more →Q/C Technologies Names Yossef Ehrlichman Chief Technology Officer to Lead Optical Processor Development
Q/C Technologies appointed Yossef Ehrlichman as Chief Technology Officer to lead its optical processor development. Dr. Ehrlichman, with 15 years of experience, aims to enhance AI systems' energy efficiency and bandwidth. He will oversee the optical processing unit program, focusing on integrating optical processing and memory into computing platforms.
Read more →Q/C Technologies Appoints Veteran Silicon Photonics Engineer Yossef Ehrlichman as Founding Manager, Photonic Integrated Circuit (PIC) Development
Q/C Technologies appointed Yossef Ehrlichman as Founding Manager for Photonic Integrated Circuit Development. He will lead the optical processing unit initiative, leveraging his 15 years of experience in silicon photonics. This appointment is part of the company's strategy to enhance its optical computing capabilities, addressing the demands of AI applications.
Read more →Q/C Technologies Relocates Headquarters to San Francisco in Proximity to World-Class Engineering Experts for Photonic Computing and Optical AI Inference Initiative
Q/C Technologies has relocated its headquarters to San Francisco to enhance its optical computing initiatives. The move aims to facilitate the development of a proprietary optical processing unit (OPU) and to attract top engineering talent from the region. The company is building a 4,800-square-foot integrated photonics lab to advance its research and development efforts.
Read more →Q/C Technologies Launches Optical Processing Unit (OPU) Initiative to Develop Proprietary Silicon Photonic Computing Architecture for AI Inference
Q/C Technologies has launched an initiative to develop a proprietary optical processing unit aimed at enhancing AI inference capabilities. This initiative seeks to address the performance and energy limitations of traditional electronic architectures by utilizing optical computing. The company is assembling a specialized engineering team and plans to file foundational patents as part of the development process.
Read more →Technologies Appoints AI Systems Leader Chelsea Voss to Board of Directors
Q/C Technologies announced the appointment of Chelsea Voss to its Board of Directors, effective January 20, 2026. Voss, a computer scientist at OpenAI, brings expertise in machine learning and AI systems development. The company is focusing on advancing its quantum-class laser processing units (qc-LPU) through partnerships aimed at enhancing photonic computing capabilities. However, Q/C Technologies must navigate risks related to product development and market conditions as it seeks to innovate in energy-efficient computing.
Read more →Quantum-Class Computing Developer Q/C Technologies Welcomes Strategic Advisor Martin Shkreli New York
Q/C Technologies, Inc. (Nasdaq: QCLS) has announced the appointment of Martin Shkreli as a Strategic Advisor, adding depth to its advisory team. Shkreli, alongside advisor James Altucher, is expected to contribute insights into technology, industry contacts, and financial innovation. The company's quantum-class computing technology, which emphasizes optical advancements, aims to deliver exceptional performance while being energy efficient. Q/C's proprietary qc-LPU100 products are reported to outperform current GPUs and quantum computers significantly, utilizing 100 times less energy.
Read more →Q/C Technologies Introduces Proprietary qc-LPU100™ Brand of Quantum-Class Laser Processing Units
Q/C Technologies announced the qc-LPU100, a quantum-class laser processing unit designed to compute at unprecedented speeds using natural light. This technology aims to outperform traditional GPUs and quantum computers while addressing energy consumption and scalability issues. The collaboration with LightSolver is expected to enhance performance in crypto mining and AI applications.
Read more →Q/C Technologies Appoints Technion Professor Dr. Steven Frankel as Senior Quantum Advisor to Advance Photonic and Quantum-Class Computing Initiatives
Q/C Technologies appointed Dr. Steven Frankel as Senior Quantum Advisor to enhance its quantum-class photonic computing initiatives. Dr. Frankel, with extensive expertise in quantum technologies, will guide the development of Q/C's Laser Processing Unit. His role aims to accelerate commercialization and improve high-performance computing solutions.
Read more →Technologies (Formerly TNF Pharmaceuticals) Commences Trading on Nasdaq Under New Ticker Symbol "QCLS" technology positions Company at forefront of new quantum-class computing paradigm
Q/C Technologies, previously known as TNF Pharmaceuticals, has commenced trading on Nasdaq under the ticker symbol QCLS. The name change reflects the company's strategic pivot towards quantum-class computing, with exclusive rights to LightSolver's laser-based processing technology for cryptocurrency applications. This transition marks a significant milestone for the company, as it aims to leverage its innovative technology to provide high-speed computing solutions. Company leadership is optimistic about the potential for sustainable value for shareholders as they advance their first-mover strategy in the industry.
Read more →TNF Pharmaceuticals Announces Name Change to Q/C Technologies and New Ticker Symbol “QCLS” to Reflect Strategic Focus on Quantum Class Photonic Computing
TNF Pharmaceuticals has rebranded as Q/C Technologies, effective September 25, 2025, and will trade under the ticker QCLS. The name change reflects a strategic shift towards quantum-class computing, particularly in the cryptocurrency sector, leveraging LightSolver's laser processing technology. This innovation aims to enhance performance and sustainability in blockchain applications.
Read more →TNF Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
TNF Pharmaceuticals Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement. The company maintained a bid price of $1.00 for 10 consecutive business days. Executive Chairman Joshua Silverman expressed satisfaction with this milestone and indicated plans for future updates to shareholders.
Read more →TNF Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
TNF Pharmaceuticals will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, at 8:00 a.m. ET. The event will take place at the Lotte New York Palace Hotel in New York City. Management will also hold one-on-one investor meetings during the conference.
Read more →Pharmaceuticals Announces Closing of $7 Million Private Placement
TNF Pharmaceuticals has successfully closed a $7 million private placement financing of convertible preferred stock, priced at a 44% premium to market. This funding involved participation from TNF's largest strategic stockholder and other existing stockholders. The capital raised is earmarked to support key development milestones for TNF's newly licensed light-based computing accelerator technology. TNF's leadership expressed optimism about the financing, viewing it as a vote of confidence in their strategy and value proposition.
Read more →Pharmaceuticals Secures Exclusive Global Rights to Innovative Light Speed Computing Accelerator for Use in Cryptocurrency Applications
TNF Pharmaceuticals has secured exclusive global rights to a light-speed computing accelerator for cryptocurrency applications through a partnership with LightSolver. This technology, which aims to outperform conventional computing methods and reduce energy costs significantly, positions TNF for substantial growth in a burgeoning market. Notably, TNF plans to undergo a name change to reflect its new focus. The partnership is expected to unlock new efficiencies in blockchain technology and respond to the industry's demand for more effective computing solutions.
Read more →TNF Pharmaceuticals Announces Reverse Stock Split For Nasdaq Listing Compliance
TNF Pharmaceuticals announced a reverse stock split at a ratio of 1-for-100 to comply with Nasdaq listing requirements. The split will reduce the number of outstanding shares significantly, from approximately 178.6 million to 1.8 million. Trading on a split-adjusted basis will commence on September 2, 2025.
Read more →TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation
TNF Pharmaceuticals has improved its financial position by significantly reducing liabilities while maintaining over $17 million in total assets. This positive change is expected to provide a stronger platform for growth and shareholder value creation. The company is also collaborating with Renova on research related to inflammation and muscle damage.
Read more →TNF Pharmaceuticals Collaborates with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Autoinflammatory Disease
TNF Pharmaceuticals has partnered with the DADA2 Foundation to conduct a Compassionate Use study of isomyosamine, a novel TNF-alpha inhibitor. This collaboration aims to provide a new treatment option for DADA2, a rare autoinflammatory disease affecting children. Isomyosamine may offer advantages over traditional biologics, including oral administration and reduced immunosuppression.
Read more →TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 Agonists
TNF Pharmaceuticals and Renova Health reported positive findings from a study on patients using GLP-1 agonists. The study aims to evaluate isomyosamine's effects on inflammation and muscle mass preservation. Initial data suggests opportunities for better diagnosis and treatment of inflammation-related conditions. The research could significantly impact patient care in outpatient settings.
Read more →